Future Science Group
Browse

sorry, we can't preview this file

Table S1.docx (12.6 kB)

Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer Table 1

Download (12.6 kB)
dataset
posted on 2023-04-14, 15:16 authored by Silv Fu, Hongxiang Huang, Kai Shang, Ganjie Tu, Peiyuan Zhong, Siling Li, Xie Zhu, Sujuan Peng, Yangyang Liu, Zhihui Lu, Li Chen

Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer Table 1

Funding

This study was funded by the National Natural Science Foundation for Young Scientists of China (grant no. 82103339) and the Medical Scientific Research Foundation from the Health Commission of Jiangxi Province, China (no. 202210473). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

History

Usage metrics

    Future Oncology

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC